McKesson Corporation reports Q4 2026 results today having shed 16% of its value in the past month alone — the question heading into the print is whether the damage is idiosyncratic or the market is right to reprice the stock.
The options market is sending a mildly encouraging signal. Calls are running ahead of puts, with the put/call ratio at 0.87 — meaningfully below its 20-day average of 0.93 and close to 1.7 standard deviations beneath that average. That tilt toward calls is a shift from earlier in April, when the PCR briefly touched its 52-week high of 1.18, suggesting defensive positioning has eased as the stock has fallen. Technical conditions are deeply oversold: the RSI14 has collapsed to 25.9, well below the oversold threshold, reflecting the pace and severity of the recent decline. The borrow market adds no alarm — cost to borrow is just 0.44%, availability is wide, and short interest at 1.7% of free float has actually fallen 6.9% over the past week. Bears are not piling in through the lending market.
The analyst community is broadly constructive but has been quietly trimming. The consensus stays at buy with 11 buy ratings and no sells, and the mean price target — around $950-$1,000 from firms including UBS and B of A Securities — implies more than 30% upside from current levels. That gap is unusual for a mega-cap health care distributor, and it frames the central debate: bulls see a business with durable pharmaceutical distribution volumes, strong free cash flow (~$5.5bn operating cash flow), and a stock that has been mis-sold alongside sector peers; bears point to Medicaid reimbursement risk, drug pricing policy uncertainty, and a forward earnings growth profile ranking in only the 19th percentile for one-year estimate momentum. The analyst-consensus-versus-price divergence scores in the 97th percentile — rarely does the Street look this much more optimistic than where the stock is trading.
The last earnings print, in February, delivered a sharp reminder of how quickly sentiment can reverse. McKesson rallied 12.5% in a single session following those Q3 results, and held most of the gain over the following five days. The pattern suggests the stock is capable of violent moves in either direction around the report. Peer context adds texture: closest comparable CAH fell 2.8% on Wednesday, while COR dropped a dramatic 17.4% in a single session this week — a read-through that has clearly weighed on McKesson and may have contributed to the sector de-rating.
Today's print is less a test of whether McKesson can grow revenues — at $408bn they dwarf most of the sector — and more a test of whether management can defend margins and guidance in a policy environment that has injected fresh uncertainty into pharmaceutical distribution economics.
See the live data behind this article on ORTEX.
Open MCK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
